News
INBX
34.10
-0.64%
-0.22
Weekly Report: what happened at INBX last week (0415-0419)?
Weekly Report · 23h ago
As more rare disease therapies launch, their prices are rising
Therapies that treat rare diseases are among the most expensive treatments for patients. The most expensive medicine in the world, Lenmeldy, comes with a wholesale price of $4.25M. Cantor Fitzgerald says the prices of rare disease therapies have been increasing since 2021.
Seeking Alpha · 6d ago
Weekly Report: what happened at INBX last week (0408-0412)?
Weekly Report · 04/15 11:45
Inhibrx Becomes Oversold (INBX)
NASDAQ · 04/12 16:05
Weekly Report: what happened at INBX last week (0401-0405)?
Weekly Report · 04/08 11:51
Weekly Report: what happened at INBX last week (0325-0329)?
Weekly Report · 04/01 11:48
Weekly Report: what happened at INBX last week (0318-0322)?
Weekly Report · 03/25 11:52
Weekly Report: what happened at INBX last week (0311-0315)?
Weekly Report · 03/18 11:50
Weekly Report: what happened at INBX last week (0304-0308)?
Weekly Report · 03/11 11:45
Inhibrx Inc reports results for the quarter ended in December - Earnings Summary
Inhibrx Inc reports results for the quarter ended in December. Revenue rose 496.4% to $1.63 million from a year ago. The company reported a quarterly loss of $93.6 million. Wall Street expected the company to report a loss of -$1.73 per share.
Reuters · 03/04 12:01
Weekly Report: what happened at INBX last week (0226-0301)?
Weekly Report · 03/04 11:49
Inhibrx Inc <INBX.OQ> expected to post a loss of $1.04 a share - Earnings Preview
Inhibrx Inc expected to post a loss of $1.04 a share - Earnings Preview. The company is expected to report a 194.1% increase in quarterly revenue to $50 thousand from $17 thousand a year ago.
Reuters · 03/01 11:03
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX) and Inhibrx (INBX)
TipRanks · 02/29 05:30
Inhibrx reports Q4 results
Inhibrx reports Q4 results Feb. 28, 2024 4:00 PM ET. Q4 net loss was $93.6M. As of December 31, 2023, cash and cash equivalents were $277.9M. The company is expected to report quarterly results on February 28.
Seeking Alpha · 02/28 21:00
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 02/28 15:25
Weekly Report: what happened at INBX last week (0219-0223)?
Weekly Report · 02/26 12:05
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
NASDAQ · 02/22 22:15
Weekly Report: what happened at INBX last week (0212-0216)?
Weekly Report · 02/19 12:08
Inhibrx, Inc.: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 02/14 23:00
Weekly Report: what happened at INBX last week (0205-0209)?
Weekly Report · 02/12 11:54
More
Webull provides a variety of real-time INBX stock news. You can receive the latest news about Inhibrx, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About INBX
Inhibrx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company’s pipeline is focused on oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, and INBRX-109. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). AATD is an inherited disease that causes an increased risk of developing pulmonary disease defined by progressive loss of lung tissue and function and is associated with decreased life expectancy. INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2.